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Abstract
Background: Recent studies have implicated variants of the transcription factor 7-like 2 (TCF7L2)
gene in genetic susceptibility to type 2 diabetes mellitus in several different populations. The aim of
this study was to determine whether variants of this gene are also risk factors for type 2 diabetes
development in a UK-resident South Asian cohort of Punjabi ancestry.
Methods: We genotyped four single nucleotide polymorphisms (SNPs) of TCF7L2 (rs7901695,
rs7903146, rs11196205 and rs12255372) in 831 subjects with diabetes and 437 control subjects.
Results: The minor allele of each variant was significantly associated with type 2 diabetes; the
greatest risk of developing the disease was conferred by rs7903146, with an allelic odds ratio (OR)
of 1.31 (95% CI: 1.11 – 1.56, p = 1.96 × 10-3). For each variant, disease risk associated with
homozygosity for the minor allele was greater than that for heterozygotes, with the exception of
rs12255372. To determine the effect on the observed associations of including young control
subjects in our data set, we reanalysed the data using subsets of the control group defined by
different minimum age thresholds. Increasing the minimum age of our control subjects resulted in
a corresponding increase in OR for all variants of the gene (p ≤ 1.04 × 10-7).
Conclusion: Our results support recent findings that TCF7L2 is an important genetic risk factor
for the development of type 2 diabetes in multiple ethnic groups.
Background
The search for genes associated with type 2 diabetes mel-
litus has frequently been complicated by small effect sizes
and poor reproducibility between studies. The recent
identification of common polymorphisms within the
transcription factor 7-like 2 (TCF7L2) gene as risk factors
for type 2 diabetes, however, provides fresh hope of
unravelling the genetic basis of this complex disease. The
association with a microsatellite marker (DG10S478) in
intron 3 of TCF7L2 was first reported by Grant et al. [1] in
Icelandic subjects and associations with surrogate markers
were subsequently confirmed in several other populations
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[2-11]. Polymorphisms of the TCF7L2 gene demonstrate
the strongest and most reproducible association with type
2 diabetes of any gene reported to date; recent large-scale
meta-analyses by Florez [12] and Cauchi et al. [13] reveal
associations between the TCF7L2  SNP rs7903146 and
type 2 diabetes with p values of < 10-80 and ~10-140 respec-
tively. The precise mechanisms by which this gene affects
diabetes risk are not known, but it is thought to influence
insulin secretion [8,10,11,14], possibly through its role in
the Wnt signalling pathway [7,15], and may also affect
insulin resistance [10,11].
The South Asian population is genetically heterogeneous
and is comprised of individuals originating from India,
Pakistan and Bangladesh. In UK-resident South Asian
populations, type 2 diabetes is around 6 times more com-
mon than in the indigenous white Caucasian population,
affecting over 10% of South Asian adults [16]. Despite the
high risk of the disease, few studies have attempted to
characterise its genetic basis in this ethnic group. Variants
of TCF7L2 have been studied in two South Asian cohorts
to date; a UK-resident population of South Indian origin
[7] and a cohort from Pune, western India [11]. The gene
has not previously been investigated in any population
from the north of the Indian subcontinent. In this study,
therefore, we investigated the association of common pol-
ymorphisms within the TCF7L2 gene with type 2 diabetes
in a well-characterized UK-resident South Asian popula-
tion of Punjabi ancestry, originating predominantly from
the Mirpur area of Azad Kashmir, Pakistan.
Methods
Type 2 diabetic subjects (N = 831) were recruited as part
of the United Kingdom Asian Diabetes Study (UKADS), a
multiple risk factor intervention trial investigating the
impact of a culturally-sensitive, enhanced diabetes care
package on the risk of cardiovascular disease in South
Asian type 2 diabetes patients living in Birmingham and
Coventry, UK. All subjects were of Punjabi ancestry, con-
firmed over three generations, and originated predomi-
nantly from the Mirpur area of Azad Kashmir, Pakistan.
Diabetes was defined using the WHO criteria [17]. Ethni-
cally-matched normoglycaemic control subjects (N =
437) were recruited from the same geographical areas
through community screening. Information concerning
the relatedness between any subjects in the study was not
collected. Normal glucose tolerance was defined as fasting
glucose < 6 mmol/l and 2 hr glucose < 7.8 mmol/l on a 75
g oral glucose tolerance test (OGTT). Where OGTT was
not feasible, normal glucose tolerance was defined as ran-
dom blood glucose < 7 mmol/l. Venous blood was col-
lected from each subject after obtaining informed consent
and genomic DNA extracted using an adaptation of the
Nucleon®  protocol (Nucleon Biosciences, Coatbridge,
UK). The study was approved by the East Birmingham
Research and Ethics Committee.
SNP selection and genotyping
We genotyped four single nucleotide polymorphisms
(SNPs: rs7901695, rs7903146, rs11196205 and
rs12255372) that showed association with type 2 diabetes
in the study by Grant et al. [1]. Genotyping was carried out
using TaqMan SNP Genotyping Assays (Applied Biosys-
tems, Warrington, UK) and fluorescence was measured
using an ABI 7900 Sequence Detection System (Applied
Biosystems). Genotyping success rate was 98.4%. Approx-
imately 20% of the samples were re-genotyped to estimate
error rate, which was zero for all SNPs.
Statistical analyses
Genotype frequencies for each SNP were checked for
Hardy-Weinberg equilibrium using a X2 goodness-of-fit
test. Pairwise linkage disequilibrium (LD) was estimated
using Haploview version 3.2 [18]. Alleles and genotypes
were tested for association with type 2 diabetes using
logistic regression. Association between genotypes and
continuous variables was tested using analysis of variance
(ANOVA). The significance of the relationship between
odds ratio (OR) and minimum age threshold was deter-
mined using linear regression. All of the above statistical
analyses were implemented in SPSS version 13.0 (SPSS
Inc, Chicago IL). Power calculations were performed
using Excel (Microsoft® Office Excel,© 2003).
Results
The clinical characteristics of the subjects in our study are
shown in Table 1. Age of diagnosis, high density lipopro-
tein (HDL) cholesterol and HbA1c data were available for
subjects with diabetes only. Body mass index (BMI), waist
circumference and blood pressure measurements were
available for both the diabetic group and 252 subjects
from the control group.
The pattern and strength of pairwise LD between SNPs
(Figure 1) was similar to that seen in the CEPH (CEU)
HapMap samples, Utah residents with ancestry from
northern and western Europe [19], and other previously
published studies involving white Caucasian cohorts
[5,9,20].
Statistical power, calculated using the number of subjects
successfully genotyped, was greater than 80% for all SNPs
with the exception of rs12255372. As the power of the
association test for this SNP was 71.1%, we would not
have been able to confidently accept the hypothesis of no
association if the results had not been significant. Given
the results of the present study, however, this finding is
largely redundant in the context of our manuscript. It is
interesting to note that, despite a smaller control group,BMC Medical Genetics 2008, 9:8 http://www.biomedcentral.com/1471-2350/9/8
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both statistical power and the significance of the associa-
tions were greater when using a control group age cut-off
of 46 years (power ≥ 94% and p ≤ 4.90 × 10-4 for all vari-
ants) compared to an age cut-off of 35 years.
Association results
In agreement with previous studies, the minor allele of
each SNP was significantly associated with type 2 diabetes
(Table 2). The strongest association was seen for the vari-
ant rs7903146, with an allelic OR of 1.31 (95% CI 1.11 –
1.56, p = 1.96 × 10-3). For most variants, the risk of type 2
diabetes mellitus among minor allele homozygotes was
greater than that among heterozygotes, supporting a mul-
tiplicative model of inheritance. This was not the case for
rs12255372 (Table 2); however, the genotype distribution
at this SNP did not conform to Hardy-Weinberg expecta-
tions in the control group (p = 0.02). There appeared to be
an excess of minor allele homozygotes in this group,
which may account for the lower than expected OR for
this genotype. Genotypes of the variants studied were not
significantly associated with any clinical, biochemical or
morphological characteristic after correction for multiple
testing. For all variants, within both the case and control
groups, there was a trend suggesting that subjects with the
rare allele homozygote genotypes had reduced BMI,
although this did not reach statistical significance.
Effect of control group minimum age thresholds
As type 2 diabetes is a relatively late-onset disease, includ-
ing young individuals within the control group could
potentially interfere with association tests, due to the pos-
sibility that these individuals may develop the disease
later in life. One commonly used method for minimising
this problem is to ensure that the mean age of the control
group is at least equal to the mean age at diagnosis of sub-
jects with diabetes. In our study cohort, the mean age of
the control group was significantly greater than the mean
age at diagnosis of the diabetic group (55.0 vs. 49.6 years,
p = 4.37 × 10-13, Table 1), suggesting that the age of con-
trol subjects was unlikely to influence our findings. To fur-
ther explore the effect of including young control subjects
on the strength of association, we compared the allelic
ORs calculated for each SNP using subsets of our control
group defined by different minimum age thresholds.
When increasing minimum age thresholds were applied,
there was a corresponding increase in OR up to an age cut-
off of 46 years (p ≤ 1.04 × 10-7, Figure 2). When the mini-
mum age was increased beyond this point, the relation-
ship with OR deteriorated. It seems likely that this
deterioration was due to decreasing numbers of control
subjects as more individuals were dropped from the data
Pairwise linkage disequilibrium (LD) between the studied var- iants Figure 1
Pairwise linkage disequilibrium (LD) between the 
studied variants. LD estimated as r2 using Haploveiw ver-
sion 3.2. Strong LD is evident between all SNPs. The pattern 
of LD is similar to that shown in the CEPH (CEU) HapMap 
samples, Utah residents with ancestry from northern and 
western Europe, and other previously published studies 
involving white Caucasian cohorts.
Table 1: Clinical characteristics of subjects studied
Diabetic 
subjects
Control 
subjects
n 831 437
Gender (M/F) 450/381 219/218
Age at study (years) 56.9 ± 12.1 55.0 ± 11.8
Age at diagnosis (years) 49.6 ± 11.9 N/Aa
BMI (kg/m2) 28.3 ± 4.7 28.1 ± 4.9b
Waist circumference (cm) 102.4 ± 10.7 99.8 ± 13.1b
Systolic blood pressure 
(mm Hg)
140.5 ± 20.9 135.7 ± 20.4b
Diastolic blood pressure 
(mm Hg)
84.1 ± 11.5 85.1 ± 12.1b
HDL cholesterol (mmol/l) 1.3 ± 0.5 NDc
HbA1c (%) 8.3 ± 1.9 NDc
Data are expressed as means ± standard deviation (SD). Mean age of 
control subjects at the time of the study was significantly greater than 
the mean age at diagnosis of the case subjects (p = 4.37 × 10-13). aN/A 
= not applicable. bBMI, waist circumference and blood pressure 
measurements were only available for 252 control subjects. cND = 
data not determined.BMC Medical Genetics 2008, 9:8 http://www.biomedcentral.com/1471-2350/9/8
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set. The relationship between minimum age and OR was
apparent for all variants, and on average the OR increased
from 1.29, using an age cut-off of 35 years, to 1.45, using
an age cut-off of 46 years.
Discussion
Our results provide important confirmation that variants
of the TCF7L2 gene are strongly associated with type 2 dia-
betes in populations of South Asian origin, with similar
effect sizes to those seen in white Caucasian populations.
Two of the variants (rs7903146 and rs12255372) have
been studied previously in South Asian cohorts [7,11].
Allele frequencies for rs7903146 in our Punjabi popula-
tion were similar to those reported in these studies,
whereas the minor allele of rs12255372 appeared to be
slightly more common in our cohort compared with these
Indian populations.
Our data support the multiplicative model of inheritance
for the TCF7L2 SNPs proposed by Grant et al. [1], except
for the rs12255372 variant. This may be due to the minor
departure from Hardy-Weinberg equilibrium observed in
the control group for this SNP. All samples were re-geno-
typed for rs12255372 using the same technique but with
fresh reagents. To rule out the possibility that the observed
excess of minor allele homozygotes in the control group
was due to systematical genotyping error, all subjects in
this group previously genotyped as TT were genotyped by
RFLP, using primers designed with the web-based tool
SNP Cutter [21] and the enzyme Tsp509 (details available
upon request). The rationale behind this latter method
was that any individual falsely genotyped as TT by the
TaqMan method would be genotyped as CT or CC by the
RFLP method. Neither method revealed any inconsisten-
cies with the initial genotyping. It seems likely, therefore,
Relationship between allelic odds ratio (OR) and control  group minimum age threshold Figure 2
Relationship between allelic odds ratio (OR) and con-
trol group minimum age threshold. Allelic OR is signifi-
cantly associated with minimum age threshold for all variants: 
rs7901695 (r2 = 0.95, p = 8.01 × 10-8), rs7903146 (r2 = 0.95, 
p = 1.04 × 10-7), rs11196205 (r2 = 0.98, p = 1.18 × 10-9), 
rs12255372 (r2 = 0.95, p = 4.05 × 10-8).
1.2
1.25
1.3
1.35
1.4
1.45
1.5
35 37 39 41 43 45
Minimum age threshold of control group (Years)
O
d
d
s
 
R
a
t
i
o
 
(
O
R
)
Black circles = rs11196205
White circles = rs7903146
Black squares = rs7901695
White squares = rs12255372
 
Table 2: Association of TCF7L2 variants with type 2 diabetes mellitus among UK-resident South Asians
SNP Allele Diabetic 
subjects Fa
Control 
subjects Fa
Genotype Diabetic sub-
jects n (%)b
Control sub-
jects n (%)b
Allelic ORc 
(95% CI)
Het ORc,d 
(95% CI)
Hom ORc,d 
(95% CI)
T 0.65 0.71 TT 362 (43.7) 226 (51.7) 1.29 
(1.09 – 1.54)
1.31 
(1.02 – 1.68)
1.65 
(1.12 – 2.44)
rs7901695 CT 355 (42.9) 169 (38.7)
C 0.35 0.29 CC 111 (13.4) 42 (9.6) p = 3.60 × 10-3 p = 0.032 p = 0.012
C 0.64 0.71 CC 352 (42.5) 222 (51.4) 1.31 
(1.11 – 1.56)
1.37 
(1.07 – 1.76)
1.66 
(1.13 – 2.44)
rs7903146 CT 360 (43.5) 166 (38.4)
T 0.36 0.29 TT 116 (14.0) 44 (10.2) p = 1.96 × 10-3 p = 0.014 p = 9.74 × 10-3
G 0.53 0.59 GG 229 (27.5) 159 (36.5) 1.30 
(1.11 – 1.54)
1.46 
(1.12 – 1.89)
1.65 
(1.18 – 2.30)
rs11196205 CG 417 (50.2) 199 (45.6)
C 0.47 0.41 CC 185 (22.3) 78 (17.9) p = 1.10 × 10-3 p = 5.29 × 10-3 p = 3.33 × 10-3
G 0.68 0.73 GG 382 (46.8) 241 (55.4) 1.26 
(1.05 – 1.51)
1.43 
(1.11 – 1.83)
1.37 
(0.92 – 2.05)
rs12255372 GT 346 (42.3) 153 (35.2)
T 0.32 0.27 TT 89 (10.9) 41 (9.4) p = 3.60 × 10-3 p = 5.23 × 10-3 p = 0.127
aF = Allele frequency. bGenotype frequency expressed as number of individuals, n – values in parentheses indicate percentage. cOR = odds ratio, 95% CI = 
95% confidence interval. dGenotype odds ratios calculated compared with homozygotes for common allele; het OR = odds ratio for heterozygous 
genotype, hom OR = odds ratio for minor allele homozygous genotype. All values were calculated using the full dataset, the minimum age of control 
subjects being 35 years.BMC Medical Genetics 2008, 9:8 http://www.biomedcentral.com/1471-2350/9/8
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that the minor departure from Hardy-Weinberg equilib-
rium is purely due to chance sampling. It is worth noting
that Humphries et al. [7] found no statistically significant
evidence for a multiplicative model of inheritance for this
SNP in a South Indian population.
A recent paper [22] has shown that a TCF7L2 haplotype
(HapBT2D), characterised by the presence of the
rs7903146 T allele, is associated with decreased BMI in
subjects with type 2 diabetes. In this study we observed a
similar trend, replicated for the minor allele of all vari-
ants, although this did not reach statistical significance.
Unlike Helgason et al., however, we observed this trend
within both the case and control groups. More data will be
needed to investigate this relationship further.
Data concerning the relatedness between subjects in the
cohort were not available in this study. It is therefore pos-
sible that some individuals are genetically related to oth-
ers in the cohort, leading to non-independence of
genotypes. Such cryptic relatedness potentially increases
the likelihood of obtaining a false positive result in tests
of genetic association, and as such must be considered as
a possible limitation of our study. Given the documented
reproducibility of the association between TCF7L2 and
type 2 diabetes, however, we do not believe that cryptic
relatedness has affected the results presented in this man-
uscript.
Our study highlights the importance of implementing
minimum age thresholds when selecting control subjects
for genetic studies of type 2 diabetes. Not implementing
these thresholds may produce an artificially low OR, as
young individuals in the control group may develop type
2 diabetes later in life and are therefore not true controls.
In our study this resulted in reduced statistical power
(increasing the likelihood of false negative results), a fac-
tor which could become increasingly important when
studying risk factors with smaller effect sizes. The effect
that a control group minimum age threshold has on an
association test will depend on the prevalence of disease
in the studied population. The marked effect reported in
this manuscript is probably due to the relatively high
prevalence of type 2 diabetes in UK-resident South Asian
populations, as young control subjects have a greater
chance of later developing the disease. In other popula-
tions, such as those of white Caucasian origin, these
thresholds may have a smaller effect.
Conclusion
In conclusion, our results add to the rapidly expanding
body of evidence that implicates TCF7L2 as an important
risk factor for type 2 diabetes in multiple ethnic groups.
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